A 41-year-old nurse from Severance shopping for a solution to her overactive bladder symptoms found a way to regain full control thanks to an innovative procedure. Sarah Avrech said goodbye to a life ...

Axonics (NASDAQ:AXNX) said it acquired a lead placement solution from Radian which complements the company's existing sacral neuromodulation (SNM) offering. The company acquired the assets of Radian ...

This x-ray of the pelvis shows an electronic nerve-stimulating device in the right iliac fossa. The procedure is ideal in this population because it is minimally invasive and highly efficacious The ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

Medtech analysts at Needham & Co. surveyed 25 urologists that reported doing a median of 30 sacral neuromodulation procedures a year. While the survey implications weren't necessarily bad for Axonics, ...

Sacral neuromodulation may not work for everyone, but Axonics is hoping to more accurately identify those who may indeed be good candidates for the technology. The devicemaker has acquired a new ...

Competition in the sacral neuromodulation space continues to breed new options for patients with bladder and bowel dysfunction. Irvine, CA-based Axonics now has FDA approval for its recharge-free ...

Medical technologies guidance 50 has been migrated to HealthTech guidance 554. The recommendations and accompanying content remain unchanged. This guidance replaces the NICE medtech innovation ...

Medical device maker Boston Scientific said on Monday it had agreed to buy Axonics for $3.7 billion, gaining access to devices used to improve bladder function. The deal marks Boston Scientific's ...

Medical device giant Boston Scientific announced a $3.7 billion deal on Monday to augment its urology portfolio. The company is acquiring Axonics, a maker of neurostimulation devices that treat ...

1 randomised controlled trial (5 publications: McVary et al. 2019, McVary and Roehrborn 2018, Roehrborn et al. 2017, McVary et al. 2016a, McVary et al. 2016b) 1 prospective observational study (3 ...